<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positiv
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Candel-Therapeutics-Inc-US1374041093">Candel Therapeutics Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Proactive Investors</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 4 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.proactiveinvestors.com/companies/news/1089013?SNAPI">Candel Therapeutics reports extended survival in Phase 2a lung cancer trial of CAN-2409</a>
    </div>

      <div class="me-0 me-md-5">
        Candel Therapeutics Inc (NASDAQ:CADL) has reported updated clinical data showing extended survival outcomes from its ongoing phase 2a trial of aglatimagene besadenovec (CAN-2409) in patients with advanced non-small cell lung cancer (NSCLC) who had previously shown an inadequate response to immune checkpoint inhibitors (ICIs). The additional 12 months of follow-up data indicate that 50% of the 4...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Candel-Therapeutics-Inc-US1374041093">Candel Therapeutics Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 4 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/03/17/3257128/0/en/Candel-Therapeutics-Reports-Extended-Survival-Tail-Observed-in-Trial-of-Aglatimagene-Besadenovec-CAN-2409-in-Advanced-Non-Small-Cell-Lung-Cancer-Patients-with-Inadequate-Response-t.html">Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors</a>
    </div>

      <div class="me-0 me-md-5">
        NEEDHAM, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to help patients with cancer, today announced an additional 12 months of extended follow-up from its study of aglatimagene plus valacyclovir in combination with continued ICI therapy in pa...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positiv
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Candel-Therapeutics-Inc-US1374041093">Candel Therapeutics Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Proactive Investors</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 4 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.proactiveinvestors.ca/companies/news/1088800?SNAPI">Candel Therapeutics strengthens balance sheet as lead cancer therapy advances</a>
    </div>

      <div class="me-0 me-md-5">
        Candel Therapeutics Inc (NASDAQ:CADL) is advancing plans to bring its lead cancer immunotherapy toward potential commercialization, outlining new phase 3 trials and a planned regulatory filing while reporting its fourth quarter and full-year 2025 financial results. “During the quarter, we made meaningful progress across our clinical pipeline and pre-commercial readiness, entering 2026 with stro...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Candel-Therapeutics-Inc-US1374041093">Candel Therapeutics Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 4 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/03/12/3254591/0/en/Candel-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Recent-Corporate-Highlights.html">Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights</a>
    </div>

      <div class="me-0 me-md-5">
        NEEDHAM, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to help patients fight cancer, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a corporate update.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Candel-Therapeutics-Inc-US1374041093">Candel Therapeutics Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 4 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/03/09/3251795/0/en/Candel-Therapeutics-To-Present-New-Data-after-Extended-Follow-Up-from-Randomized-Phase-3-Trial-of-Aglatimagene-Besadenovec-in-Localized-Prostate-Cancer-at-the-American-Urological-A.html">Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting</a>
    </div>

      <div class="me-0 me-md-5">
        NEEDHAM, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that an abstract was accepted for oral presentation in the Practice-changing, Paradigm-shifting Clinical Trials in Urology session...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Candel-Therapeutics-Inc-US1374041093">Candel Therapeutics Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 4 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/03/02/3247866/0/en/Candel-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html">Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</a>
    </div>

      <div class="me-0 me-md-5">
        NEEDHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that on February 28, 2026, the Compensation Committee of Candel&#39;s Board of Directors (the Board) granted to one new employee, stoc...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Candel-Therapeutics-Inc-US1374041093">Candel Therapeutics Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 4 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/02/24/3243548/0/en/Candel-Therapeutics-to-Present-at-TD-Cowen-s-46th-Annual-Health-Care-Conference-in-Boston.html">Candel Therapeutics to Present at TD Cowen&#39;s 46th Annual Health Care Conference in Boston</a>
    </div>

      <div class="me-0 me-md-5">
        NEEDHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel&#39;s President and Chief Executive Officer, will present at TD Cowen&#39;s 46th Annual H...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Candel-Therapeutics-Inc-US1374041093">Candel Therapeutics Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Proactive Investors</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 5 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.proactiveinvestors.com/companies/news/1087691?SNAPI">Candel Therapeutics prices $100M public offering</a>
    </div>

      <div class="me-0 me-md-5">
        Candel Therapeutics Inc (NASDAQ:CADL) told investors on Thursday it has priced its previously disclosed public offering of about 18.3 million shares at $5.45 per share. The clinical-stage biopharmaceutical company said the offering is expected to generate gross proceeds of about $100 million, before deducting underwriting discounts, commissions and other expenses.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/news/Candel-Therapeutics-Inc-US1374041093/load_more?page=4">
      Mehr Neuigkeiten anzeigen
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>